Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Helene Labussiere, MD, PhD, Madeleine Etienne, CRA, Marie-Pierre Fort, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Kaddour Chabane, Eric Lippert, MD, Mohamad Sobh, Pharm.M., Stephanie Dulucq, MD, Stephane Morisset, Stat., Mauricette Michallet, Francois-Xavier Mahon, MD, PhD, Gabriel Etienne, MD, PhD

Blood (2011) 118 (21): 1684.

https://doi.org/10.1182/blood.V118.21.1684.1684

Published: 2011

Journal Articles

Shorter Time to Achieve a Major Molecular Response (MMR) Is Predictive of a Faster Complete Molecular Response in CML: A Study of Characteristics and Outcomes of a Cohort of CML Patients in MMR

Mauricette Michallet, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Madeleine Etienne, CRA, Elodie Gadolet, CRA, Helene Labussiere, MD, Sandrine Hayette, PhD, Franck E. Nicolini, MD, PhD

Blood (2011) 118 (21): 1691.

https://doi.org/10.1182/blood.V118.21.1691.1691

Published: 2011

Journal Articles

The Achievement of Early Major Molecular Response In Early Chronic Phase Chronic Myeloid Leukemia on Imatinib 400 Mg/Day Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival.

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Lila Gilis, MD, Madeleine Etienne, CRA, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Helene Labussiere, MD, Luc Gerland, MD, Damien Waz, MStud, Mohamad Sobh, Pharm., M, Stephane Morisset, Stat., Mauricette Michallet

Blood (2010) 116 (21): 3407.

https://doi.org/10.1182/blood.V116.21.3407.3407

Published: 2010

Journal Articles

Impact of Peripheral Blood Stem Cell Recruitment on Outcome of Single or Double Autologous Hematopoietic stem Cell Transplantation for Multiple Myeloma.

Mauricette Michallet, MD PhD, Quoc-Hung Le, MD, Anne-Sophie Michallet, MD, Anne Thiebaut, MD, Emmanuelle Tavernier, MD, Jacques Troncy, MD, Xavier Thomas, MD PhD, Youcef Chelghoum, MD, Aline Praire, Elodie Gadolet, Franck E. Nicolini, MD PhD, Gilles Clapisson, Irene Philip, MD

Blood (2004) 104 (11): 5221.

https://doi.org/10.1182/blood.V104.11.5221.5221

Published: 2004

Journal Articles

Donor Lymphocyte Infusion Management and Impact on Transplant Outcome after Reduced Intensity Conditioning Allogeneic Transplantation.

Mauricette Michallet, MD, PhD, Quoc-Hung Le, MD, Anne-Sophie Michallet, MD, Anne Thiebaut, MD, Emannuelle Tavernier, MD, Hanadi Rafii, MD, Daniela Revesz, MD, Jacques Troncy, MD, Aline Praire, Elodie Gadolet, Valerie Dubois, PhD, Lucette Gebuhrer, MD, Olivier Hequet, MD, PhD, Jean-Paul Bourgeot, Franck E. Nicolini, MD, PhD

Blood (2004) 104 (11): 2305.

https://doi.org/10.1182/blood.V104.11.2305.2305

Published: 2004

Journal Articles

Kinetics of Chimerism Conversion to Total Donor Profile: Impact on Transplant Outcome after Reduced Intensity Conditioning Allogeneic Transplantation.

Mauricette Michallet, MD PhD, Quoc-Hung Le, MD, Anne-Sophie Michallet, MD, Franck E. Nicolini, MD PhD, Anne Thiebaut, MD, Emmanuelle Tavernier, MD, Hanadi Rafii, MD, Samira Mahmoudi, MD, Daniela Revesz, MD, Aline Praire, Elodie Gadolet, Valerie Dubois, PhD, Lucette Gebuhrer, MD

Blood (2004) 104 (11): 1821.

https://doi.org/10.1182/blood.V104.11.1821.1821

Published: 2004

NARROW

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Shorter Time to Achieve a Major Molecular Response (MMR) Is Predictive of a Faster Complete Molecular Response in CML: A Study of Characteristics and Outcomes of a Cohort of CML Patients in MMR

The Achievement of Early Major Molecular Response In Early Chronic Phase Chronic Myeloid Leukemia on Imatinib 400 Mg/Day Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival.

Impact of Peripheral Blood Stem Cell Recruitment on Outcome of Single or Double Autologous Hematopoietic stem Cell Transplantation for Multiple Myeloma.

Donor Lymphocyte Infusion Management and Impact on Transplant Outcome after Reduced Intensity Conditioning Allogeneic Transplantation.

Kinetics of Chimerism Conversion to Total Donor Profile: Impact on Transplant Outcome after Reduced Intensity Conditioning Allogeneic Transplantation.

Email alerts

ASH Publications

American Society of Hematology

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Shorter Time to Achieve a Major Molecular Response (MMR) Is Predictive of a Faster Complete Molecular Response in CML: A Study of Characteristics and Outcomes of a Cohort of CML Patients in MMR

The Achievement of Early Major Molecular Response In Early Chronic Phase Chronic Myeloid Leukemia on Imatinib 400 Mg/Day Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival.

Impact of Peripheral Blood Stem Cell Recruitment on Outcome of Single or Double Autologous Hematopoietic stem Cell Transplantation for Multiple Myeloma.

Donor Lymphocyte Infusion Management and Impact on Transplant Outcome after Reduced Intensity Conditioning Allogeneic Transplantation.

Kinetics of Chimerism Conversion to Total Donor Profile: Impact on Transplant Outcome after Reduced Intensity Conditioning Allogeneic Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only